Modulation of Agonist and Antagonist Interactions at Kidney Alpha 1-adrenoceptors by Nucleotides and Metal Ions
Overview
Authors
Affiliations
In order to characterize putative high- and low-affinity states of the renal alpha 1-adrenoceptor, binding sites for the selective antagonist radioligand [3H]prazosin were examined in washed membranes prepared from rat renal cortex and medulla. Norepinephrine competition curves at [3H]prazosin sites were biphasic and were best fit by a two-site model. Na+ and GTP selectively decreased the proportion of sites exhibiting a high affinity for norepinephrine. In contrast, Mg2+ facilitated high-affinity interactions of norepinephrine at the renal alpha 1-receptor. Guanine nucleotides and Na+ increased the affinity of some antagonists [( 3H]prazosin, WB-4101), but not others (phentolamine). Mg2+ again had opposite effects. The effects of ions and nucleotides on both agonist and antagonist interactions were concentration-dependent. The order of potencies for monovalent cations (Na+ greater than Li+ much greater than K+), divalent cations (Mn2+ greater than Mg2+) and nucleotides (Gpp (NH)p, GTP much greater than GMP, ATP) were similar to those reported for cyclase-coupled receptor systems. However, unlike other divalent cations Ca2+ decreased both agonist and antagonist binding, possibly due to a Ca2+-sensitive proteinase. Receptor binding properties were similar in renal cortex and medulla. Renal alpha 1-receptor sites appear to display high- and low-affinity states with respect to agonists, and the equilibrium between these states may be modulated by guanine nucleotides and mono- and divalent metal ions. Some antagonists appear to bind preferentially to sites with low agonist affinity, and this effect is probably independent of retained endogenous catecholamines.
Nickel inhibits β-1 adrenoceptor mediated activation of cardiac CFTR chloride channels.
Barman P, Cheng H, Hancox J, James A Biochem Biophys Res Commun. 2013; 432(1):46-51.
PMID: 23376720 PMC: 3686155. DOI: 10.1016/j.bbrc.2013.01.087.
Berdysheva L, Manukhin B Dokl Biol Sci. 2003; 381:522-5.
PMID: 12918423 DOI: 10.1023/a:1013357901087.
Harikumar K, Chattopadhyay A Cell Mol Neurobiol. 1998; 18(5):535-53.
PMID: 9777253 PMC: 11560197. DOI: 10.1023/a:1026383527092.
Salles J, Badia A Br J Pharmacol. 1991; 102(2):439-45.
PMID: 1673073 PMC: 1918043. DOI: 10.1111/j.1476-5381.1991.tb12192.x.
Veenstra D, Van Buuren K, Nijkamp F Br J Pharmacol. 1992; 107(1):202-6.
PMID: 1358383 PMC: 1907626. DOI: 10.1111/j.1476-5381.1992.tb14487.x.